CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases ...

CAGE Bio begins double-blind placebo-controlled clinical trial of topical DNA Aptamer therapy CGB-600 for vitiligo treatment: San Carlos, California Saturday, October 25, 2025, 12 ...

Incyte INCY has put up a stellar performance year to date on the back of better-than-expected quarterly results, and positive ...

The FDA rounded out the month with the approval of remibrutinib (Rhapside; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for patients with chronic spontaneous urticaria (CSU) ...

Kang Hoon-sik, the presidential chief of staff, headed to Europe on the 19th as the president’s special envoy for strategic ...

Incyte's growth potential and low valuation are driven by a strong pipeline and strategic focus. Read here for an investment analysis of INCY stock.

The Miss USA 2025 pageant will be held in Reno on Friday. This year's contestants include an "American Ninja Warrior" ...

Encompass Health Corp. today announced that its board of directors has declared a quarterly cash dividend on its common stock of $0.19 per share, payable on Jan. 15, 2026, to holders of record on Jan.

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: 4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA) ...

Macrobond, the leading provider of global economic and financial data and analytics, today announced a strategic integration with FactSet, a global digital platform and enterprise solutions provider.

For patients with darker skin tones, colorblind energy-based devices and longer-wavelength lasers are considered safest, according to Arielle Kauvar, MD, director of New York Laser & Skin Care and ...